Beacon Pharma gets going by Jan next - Lyophilization Articles & Reports

Beacon Pharma gets going by Jan next
7/15/2005
Financial Express
Beacon Pharmaceuticals Ltd, a Tk 1.30 billion plant designed to produce high-tech anti-cancer medicines, will start operation by January of next year (2006).
About 90 per cent civil work of the company, a concern of Orion Group, at Bhaluka of Mymensingh district has already been completed, company sources said.
"Apart from civil constructions, other technical works of the project have also progressed significantly," one source of Orion Infusion Limited told this correspondent Thursday.
He said the civil construction covering a huge 20-acre land began on May 30, 2004.
A total of Tk 800 million was invested in the first phase of the project, financed by City Bank Ltd, Social Investment Bank Ltd, Janata Bank and Agrani Bank.
He said in addition to general pharmaceutical finished formulations of specialised categories, the new plant will contain a modern, totally segregated, fully automated facility for manufacturing complete range of anti-cancer products including lyophilized antibiotics, first of its kind in Bangladesh.
In addition to fulfilling the domestic demand, the Beacon will also offer toll/contract manufacturing opportunity to the multinational companies which are in operation in Bangladesh and importing anti-cancer and other specialised products at exorbitantly high prices.
"Multinational companies which do not have manufacturing plant or direct operation in Bangladesh will be allowed to produce their products in Beacon plant at substantially lower cost and buy-back the same for marketing overseas," he added.
After commissioning, the company will help the domestic cancer patients to buy the proper medicines at comparatively cheaper rates.
"As a result, our huge foreign currency, which is being spent on cancer treatment, will be saved," the Beacon executive said.
The second phase includes production of hormones, cephalosporins (anti biotics) and other specialised items for which the investment amount will be higher than the first phase.
Telstar of Spain, a renowned pharmaceutical project developer, is the consultant of Beacon Pharma.
The project is being designed, constructed and validated in compliance with the requirements of European Regulatory Guidelines and US FDA (Food and Drug Administration).
The company will also create employment opportunity for around 1000 people.